Hinova Pharmaceuticals Inc. (SHA:688302)
China
· Delayed Price · Currency is CNY 42.60
+1.98 (4.87%)
At close: Mar 6, 2026
Hinova Pharmaceuticals Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2018 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2018 |
| Operating Revenue | 20.67 | - | - | - | - | Upgrade
|
| Other Revenue | - | 0.37 | - | 1.65 | - | Upgrade
|
| Revenue | 20.67 | 0.37 | - | 1.65 | - | Upgrade
|
| Revenue Growth (YoY) | 5535.71% | - | - | - | - | Upgrade
|
| Cost of Revenue | - | 0.34 | - | 0.77 | - | Upgrade
|
| Gross Profit | 20.67 | 0.03 | - | 0.88 | - | Upgrade
|
| Selling, General & Admin | - | 53.49 | 88 | 97.04 | 80.28 | Upgrade
|
| Research & Development | - | 174.03 | 248.27 | 251.37 | 264.93 | Upgrade
|
| Other Operating Expenses | 156.47 | 0.41 | 0.42 | 0.35 | 0.06 | Upgrade
|
| Operating Expenses | 156.47 | 227.94 | 336.69 | 348.75 | 345.27 | Upgrade
|
| Operating Income | -135.79 | -227.91 | -336.69 | -347.87 | -345.27 | Upgrade
|
| Interest Expense | - | -0.53 | -1.49 | -3.92 | -2.56 | Upgrade
|
| Interest & Investment Income | - | 19.16 | 28.62 | 22.5 | 26.97 | Upgrade
|
| Currency Exchange Gain (Loss) | - | 1.35 | 1.4 | 7.56 | -2.1 | Upgrade
|
| Other Non Operating Income (Expenses) | -0.89 | -0.43 | -0.38 | -0.17 | -0.14 | Upgrade
|
| EBT Excluding Unusual Items | -136.68 | -208.35 | -308.53 | -321.9 | -323.11 | Upgrade
|
| Gain (Loss) on Sale of Investments | - | 3.96 | 8.35 | 10.27 | -1.5 | Upgrade
|
| Gain (Loss) on Sale of Assets | - | -0 | -0.01 | -0 | -0 | Upgrade
|
| Other Unusual Items | - | 4.91 | 6.04 | 10.12 | 18.44 | Upgrade
|
| Pretax Income | -136.68 | -199.48 | -294.14 | -301.51 | -306.18 | Upgrade
|
| Income Tax Expense | 0 | 0.01 | 0.02 | - | - | Upgrade
|
| Earnings From Continuing Operations | -136.69 | -199.5 | -294.16 | -301.51 | -306.18 | Upgrade
|
| Net Income | -136.69 | -199.5 | -294.16 | -301.51 | -306.18 | Upgrade
|
| Net Income to Common | -136.69 | -199.5 | -294.16 | -301.51 | -306.18 | Upgrade
|
| Shares Outstanding (Basic) | 99 | 99 | 99 | 91 | 74 | Upgrade
|
| Shares Outstanding (Diluted) | 99 | 99 | 99 | 91 | 74 | Upgrade
|
| Shares Change (YoY) | -0.20% | 0.21% | 9.06% | 22.21% | 5.74% | Upgrade
|
| EPS (Basic) | -1.38 | -2.01 | -2.97 | -3.32 | -4.12 | Upgrade
|
| EPS (Diluted) | -1.38 | -2.01 | -2.97 | -3.32 | -4.12 | Upgrade
|
| Free Cash Flow | - | -276.63 | -354.68 | -384.13 | -247.6 | Upgrade
|
| Free Cash Flow Per Share | - | -2.79 | -3.58 | -4.23 | -3.33 | Upgrade
|
| Gross Margin | 100.00% | 8.43% | - | 53.57% | - | Upgrade
|
| Operating Margin | -656.84% | -62127.45% | - | -21072.49% | - | Upgrade
|
| Profit Margin | -661.16% | -54382.81% | - | -18264.53% | - | Upgrade
|
| Free Cash Flow Margin | - | -75410.46% | - | -23269.07% | - | Upgrade
|
| EBITDA | -133.72 | -225.83 | -334.4 | -345.96 | -342.22 | Upgrade
|
| D&A For EBITDA | 2.07 | 2.07 | 2.28 | 1.91 | 3.05 | Upgrade
|
| EBIT | -135.79 | -227.91 | -336.69 | -347.87 | -345.27 | Upgrade
|
| Revenue as Reported | - | 0.37 | - | 1.65 | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.